Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Chiba
Clinical trial register · Japan

Clinical Trials in Chiba, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Chūōku 90 Fukuoka 84 Kashiwa 72 Bunkyō City 61 Kōtoku 56
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca46 GlaxoSmithKline26 Janssen Research & Development, LLC21 Eli Lilly and Company19 Hoffmann-La Roche18 Clear sponsor filter
Site location
Chūōku90 Fukuoka84 Kashiwa72 Bunkyō City61 Kōtoku56
All 186 locations
Target enrolment
to

Trials with a site in Chiba

46 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
NCT07816666Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer
DrugsTorvutatug samrotecan·Bevacizumab
AstraZeneca
Phase 3
600
Chiba, Fukuoka, Fukushima, Gifu, Hidaka-shi, Ichihara, Kagoshima, Kobe
2026-09-24
Recruiting
AstraZeneca
Phase 3
1,330
Chiba, Fukuoka, Hiroshima, Kamakura-shi, Kawagoe-shi, Kisarazu-shi, Kita-gun, Kobe
2026-09-15
Recruiting
AstraZeneca
Phase 3
2,800
Ageo, Asahi-shi, Chiba, Fukaya, Fukui-shi, Izumisano, Izunokuni-shi, Kariya
2026-09-01
Recruiting
AstraZeneca
Phase 3
800
Amagasaki-shi, Chiba, Chitose-shi, Chūōku, Koga-shi, Minatoku, Okayama, Oyama-shi
2026-07-06
Recruiting
AstraZeneca
Phase 3
670
Chiba, Chūōku, Fukuoka, Hamamatsu, Kamakura-shi, Kanazawa, Kashiwa, Kobe
2026-05-04
Recruiting
AstraZeneca
Phase 3
1,100
Chiba, Kashiwa, Kawasaki-shi, Kōtoku, Matsuyama, Nagoya, Osaka, Suita-shi
2025-12-04
Recruiting
AstraZeneca
Phase 2
987
Chiba, Fukuoka, Fukushima, Ginowan-shi, Hachioji-shi, Hamamatsu, Hiroshima, Izumi-shi
2025-06-27
Recruiting
AstraZeneca
Phase 3
1,220
Bunkyō City, Chiba, Fukuoka, Hiroshima, Iizuka-shi, Kashiwa, Kita-gun, Kobe
2025-05-06
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
DrugSurovatamig
AstraZeneca
Phase 2
270
Chiba, Kashiwa, Kōtoku, Kumamoto, Niigata, Okayama, Osaka, Yokohama
2024-11-27
Active, closed
AstraZeneca
Phase 3
25
Bunkyō City, Chiba, Chūōku, Fukuoka, Hidaka-shi, Hiroshima, Iwakuni-shi, Kashiwa
2024-10-15
Recruiting
AstraZeneca
Phase 3
620
Bunkyō City, Chiba, Fukuyama-shi, Hirakata-shi, Hiroshima, Kanazawa, Kashiwa, Kawasaki-shi
2024-08-12
Recruiting
AstraZeneca
Phase 3
1,018
Bunkyō City, Chiba, Chuo-shi, Fukuoka, Hirakata-shi, Kobe, Kōtoku, Kumamoto
2024-08-07
Recruiting
AstraZeneca
Phase 3
788
Chiba, Hidaka-shi, Hirakata-shi, Isehara-shi, Kagoshima, Kashiwa, Kōtoku, Kumamoto
2024-08-01
Active, closed
AstraZeneca
Observational
40
Chiba, Hiroshima, Hokkaido, Hyōgo, Ibaraki, Mie, Okayama, Osaka
2024-07-16
Recruiting
AstraZeneca
Phase 3
240
Asahikawa-Shi, Bunkyō City, Chiba, Fukuoka, Hiroshima, Iruma-Gun, Kawachinagano-shi, Kawasaki-shi
2024-06-20
Recruiting
AstraZeneca
Phase 3
100
Bunkyō City, Chiba, Fuchu-shi, Kawasaki-shi, Kobe, Nagasaki, Obu-shi, Shinjuku-ku
2024-03-14
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugSurovatamig
AstraZeneca
Phase 1/2
255
Bunkyō City, Chiba, Chūōku, Fukuoka, Kashiwa, Kyoto, Okayama, Osaka
2023-12-29
Recruiting
AstraZeneca
Phase 3
1,145
Bunkyō City, Chiba, Chūōku, Fukuoka, Hidaka-shi, Hiroshima, Kashiwa, Kobe
2023-12-14
Recruiting
AstraZeneca
Phase 3
625
Akashi-shi, Bunkyō City, Chiba, Chūōku, Fukuoka, Fukushima, Gifu, Hidaka-shi
2023-11-23
Active, closed
AstraZeneca
Phase 3
1,898
Chiba, Fukuoka, Hirakata-shi, Hirosaki-shi, Kanazawa, Kashihara-shi, Kawagoe-shi, Kisarazu-shi
2023-11-21
Active, closed
AstraZeneca
Phase 3
1,902
Akashi-shi, Akita, Bunkyō City, Chiba, Chūōku, Fukuoka, Fukushima, Gifu
2023-11-14
Active, closed
AstraZeneca
Phase 3
5,511
Bunkyō City, Chiba, Chūōku, Fukuoka, Fukushima, Hirakata-shi, Hiroshima, Iruma-Gun
2023-10-05
Active, closed
TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)
NCT05729711Bronchial Asthma (Only the Patients With Severe or Intractable Bronchial Asthma Which Could Not be Controlled With the Existing Therapy)
AstraZeneca
Observational
416
Aichi, Akita, Aomori, Chiba, Fukui, Fukuoka, Gifu, Gunma
2023-04-04
Recruiting
AstraZeneca
Phase 3
4,300
Chiba, Chūōku, Fukuoka, Fukushima, Hidaka-shi, Hirakata-shi, Hiroshima, Isehara-shi
2023-03-31
Recruiting
AstraZeneca
Phase 3
3,527
Chiba, Fukuoka, Gifu, Ginowan-shi, Hanyu-shi, Hiroshima, Hitachi-shi, Isehara-shi
2022-12-13
Active, closed
AstraZeneca
Phase 3
1,174
Akashi-shi, Chiba, Chūōku, Fukuoka, Fukushima, Hiroshima, Isehara-shi, Kashiwa
2022-11-28
Recruiting
AstraZeneca
Observational
300
Aichi, Akita, Aomori, Chiba, Ehime, Fukui, Fukuoka, Fukushima
2022-06-02
Active, closed
AstraZeneca
Phase 3
1,035
Chiba, Hirakata-shi, Hirosaki-shi, Kanazawa, Kashihara-shi, Kita-gun, Kobe, Kumamoto
2022-03-25
Active, closed
AstraZeneca
Phase 3
390
Chiba, Fukuoka, Hiroshima, Kashiwa, Kōtoku, Kyoto, Niigata, Osaka
2022-02-21
Active, closed
AstraZeneca
Phase 3
791
Bunkyō City, Chiba, Fukuoka, Hidaka-shi, Hirosaki-shi, Itabashi-ku, Kashihara-shi, Kōtoku
2022-02-18
Active, closed
AstraZeneca
Phase 3
363
Bunkyō City, Chiba, Hiroshima, Kita-gun, Kitakyushu-shi, Matsumoto-shi, Nagasaki, Okayama
2022-02-15
Active, closed
AstraZeneca
Observational
1,620
Aichi, Akita, Aomori, Chiba, Ehime, Fukui, Fukuoka, Fukushima
2021-12-21
Active, closed
AstraZeneca
Phase 3
315
Chiba, Chūōku, Hidaka-shi, Hirakata-shi, Kitaadachi-gun, Kōtoku, Kumamoto, Matsuyama
2021-06-30
Active, closed
AstraZeneca
Phase 3
367
Chiba, Chūōku, Hamamatsu, Hiroshima, Itabashi-ku, Kita-gun, Kitakyushu-shi, Meguro-ku
2021-06-08
Active, closed
AstraZeneca
Phase 3
893
Chiba, Chūōku, Hidaka-shi, Hiroshima, Isehara-shi, Kagoshima, Kōtoku, Kyoto
2021-05-10
Active, closed
AstraZeneca
Phase 3
1,157
Akashi-shi, Aomori, Bunkyō City, Chiba, Chūōku, Fukushima, Hidaka-shi, Hiroshima
2021-04-26
Active, closed
AstraZeneca
Phase 3
1,371
Chiba, Chūōku, Hidaka-shi, Hirakata-shi, Isehara-shi, Kitaadachi-gun, Kōtoku, Kumamoto
2021-01-28
Active, closed
AstraZeneca
Phase 3
358
Akashi-shi, Bunkyō City, Chiba, Hiroshima, Kashiwa, Kōtoku, Kyoto, Niigata
2020-12-16
Active, closed
AstraZeneca
Phase 3
866
Akashi-shi, Bunkyō City, Chiba, Chūōku, Fukuoka, Gifu, Hidaka-shi, Hiroshima
2020-07-24
Active, closed
AstraZeneca
Phase 3
134
Chiba, Hamamatsu, Ichikawa-shi, Kawasaki-shi, Nishinomiya-shi, Osaka, Sendai
2020-07-20
Active, closed
AstraZeneca
Phase 3
1,012
Bunkyō City, Chiba, Chūōku, Fukuoka, Hamamatsu, Hirakata-shi, Hirosaki-shi, Isehara-shi
2020-07-13
Active, closed
AstraZeneca
Phase 3
818
Chiba, Fukuoka, Fukushima, Hidaka-shi, Hiroshima, Kagoshima, Kitaadachi-gun, Kōtoku
2020-04-16
Active, closed
AstraZeneca
Phase 3
140
Chiba, Kita-gun, Sagamihara-shi, Sendai, Shinjuku-ku
2019-10-29
Active, closed
AstraZeneca
Phase 3
724
Bunkyō City, Chiba, Chūōku, Fukuoka, Hiroshima, Kurume-shi, Musashino-shi, Nagoya
2018-11-30
Active, closed
AstraZeneca
Phase 3
1,324
Bunkyoku, Chiba, Fukuoka, Hiroshima, Iizuka, Kanazawa, Kōtoku, Kumamoto
2017-10-11
Active, closed
AstraZeneca
Phase 3
1,837
Chiba, Chūōku, Fukuoka, Hidaka-shi, Hiroshima, Isehara-shi, Kagoshima, Kashiwa
2014-04-22
Rows per page Showing 1–46 of 46
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/chiba

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 46 of those studies with a site in Chiba that also match the filters currently applied.

How many clinical trials are recruiting in Chiba?

20 of the 46 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 26 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Chiba), 46 studies
PhaseStudiesRecruitingShare
Phase 3391684.8%
Observational418.7%
Phase 2224.3%
Phase 1/2112.2%

Most active sponsors

Lead sponsors with the most studies (Chiba)
Lead sponsorStudiesRecruiting
AstraZeneca4620
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.